Phase 2 N=15 Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Locally Advanced or Metastatic NSCLC
Primary: Objective Response Rate — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Phase 2 N=17 A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Non Small Cell Lung Cancer
Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants
Phase 4 N=60 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…
Phase 2 N=41 Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 2 Percentage of participants
Phase 2 N=13 Afatinib in NSCLC With HER2 Mutation
NSCLC
Primary: Disease Control (Defined as Complete or Partial Response, or Disease Stabilisation Lasting at Least 12 Weeks) — 7; 6; 4; 5 Participants
Phase 2 N=29 Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Non Small Cell Lung Cancer
Primary: Overall Response Rate — 5 Participants
N/A N=314 T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
Non-small Cell Lung Cancer Stage III · Non-Small-Cell Lung Cancer Metastatic
Primary: Number of Patients With T790M Mutation Detected by Amplification Refractory Mutation System (ARMS) Assay — 97 participants
N/A N=24 Understanding Mechanisms of Acquired Resistance to BIBW2992
Non-small Cell Lung Cancer · EGFR Mutations
Primary: Number of Participants That Have a T790M Mutation on Their Progression Biopsy. — 4 Participants
Phase 2 N=109 BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Lung Cancer
Primary: Progression Free Survival — 16; 10.5 months
Phase 2 N=60 Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Non-small Cell Lung Cancer
Primary: Resistance Mechanism — 23; 1; 3; 4 participants
Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Phase 3 N=168 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Phase 2 N=129 LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response (OR) as Determined by RECIST 1.0 — 62.0 percentage of participants
Phase 2 N=210 Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
N/A N=462 The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) — 9.89; 27.7 Months
Phase 2 N=25 Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Progression Free Survival — 64 percentage of participants
Phase 4 N=107 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Primary: Objective Response Rate (ORR) (Investigator) — 69.8; 30.2 Percentage of Participants
Phase 2 N=218 BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Phase 2 N=688 A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Tested Positive for EGFR Mutations — 8.1 percentage of participants
Phase 3 N=345 BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-Free Survival (PFS) Time — 11.17; 6.90 Months. — p=0.0002
Phase 2 N=18 Afatinib in NSCLC With HER2 Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Patients With Objective Response (OR) in Part A According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 — 0.0 Percentage of participants
Phase 2 N=171 Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
Non-Small Cell Lung Cancer
Primary: ORR According to RECIST 1.1 by Independent Review — 62.0 % of participants
Phase 3 N=3,014 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
Lung Cancer
Primary: Overall Survival (OS) — 22.8 Months
Phase 2 N=6 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days
Phase 2 N=46 First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
Pulmonary Cancer
Primary: Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria. — 0 Percent of Participants
Phase 2 N=225 A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Advanced Non-small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part) — 0; 0; 2; 0 Participants
Phase 3 N=364 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-free Survival — 11.01; 5.59 months — p=<0.0001
Phase 2 N=11 Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 — 1 Participants
Phase 4 N=24 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation — 13.7 months